1. Home
  2. LEE vs SABS Comparison

LEE vs SABS Comparison

Compare LEE & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEE
  • SABS
  • Stock Information
  • Founded
  • LEE 1890
  • SABS 2014
  • Country
  • LEE United States
  • SABS United States
  • Employees
  • LEE N/A
  • SABS N/A
  • Industry
  • LEE Newspapers/Magazines
  • SABS Biotechnology: Pharmaceutical Preparations
  • Sector
  • LEE Consumer Discretionary
  • SABS Health Care
  • Exchange
  • LEE Nasdaq
  • SABS Nasdaq
  • Market Cap
  • LEE 33.8M
  • SABS 31.2M
  • IPO Year
  • LEE N/A
  • SABS N/A
  • Fundamental
  • Price
  • LEE $4.23
  • SABS $3.25
  • Analyst Decision
  • LEE
  • SABS Strong Buy
  • Analyst Count
  • LEE 0
  • SABS 3
  • Target Price
  • LEE N/A
  • SABS $9.00
  • AVG Volume (30 Days)
  • LEE 33.0K
  • SABS 333.0K
  • Earning Date
  • LEE 12-11-2025
  • SABS 11-06-2025
  • Dividend Yield
  • LEE N/A
  • SABS N/A
  • EPS Growth
  • LEE N/A
  • SABS N/A
  • EPS
  • LEE N/A
  • SABS N/A
  • Revenue
  • LEE $581,809,000.00
  • SABS $114,698.00
  • Revenue This Year
  • LEE N/A
  • SABS N/A
  • Revenue Next Year
  • LEE N/A
  • SABS N/A
  • P/E Ratio
  • LEE N/A
  • SABS N/A
  • Revenue Growth
  • LEE N/A
  • SABS N/A
  • 52 Week Low
  • LEE $3.79
  • SABS $1.00
  • 52 Week High
  • LEE $19.37
  • SABS $6.60
  • Technical
  • Relative Strength Index (RSI)
  • LEE 40.61
  • SABS 69.98
  • Support Level
  • LEE $4.40
  • SABS $2.90
  • Resistance Level
  • LEE $4.97
  • SABS $3.19
  • Average True Range (ATR)
  • LEE 0.35
  • SABS 0.23
  • MACD
  • LEE 0.01
  • SABS 0.05
  • Stochastic Oscillator
  • LEE 35.09
  • SABS 95.04

About LEE Lee Enterprises Incorporated

Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: